{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:19:59Z","timestamp":1780636799290,"version":"3.54.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Development of a stability-indicating high-performance liquid chromatography (HPLC) method for pyrimethamine analysis, with subsequent application of that method to assess the 90-day stability of a pyrimethamine suspension compounded from bulk USP-grade pyrimethamine powder, is described.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A stability-indicating method of HPLC with ultraviolet detection specific to pyrimethamine was developed according to pharmacopeial recommendations and validated. The method was applied to investigate the stability of a 2-mg\/mL pyrimethamine suspension in a vehicle consisting of Ora-Plus and Ora-Sweet (Perrigo) over a period of 90 days. Three replicate test preparations were stored at room temperature or refrigerated at 4.3\u20135.2 \u00b0C, and samples were analyzed in duplicate immediately after preparation and on study days 1, 2, 4, 7, 10, 14, 21, 30, 48, 60, 75, and 90.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The 2-mg\/mL suspension of pyrimethamine in Ora-Plus and Ora-Sweet retained 90\u2013110% of the labeled potency to 90 days at both temperature ranges. However, color changes in the samples stored at room temperature observed at day 60 indicated that a beyond-use date less than 90 days from the preparation date should be specified when the suspension is to be stored at room temperature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The study demonstrated that USP-grade pyrimethamine powder can be formulated as a 2-mg\/mL suspension in a vehicle of Ora-Plus and Ora-Sweet and is stable when stored at room temperature and when refrigerated, in amber plastic bottles, for 48 and 90 days, respectively.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2146\/ajhp160551","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T16:55:40Z","timestamp":1512752140000},"page":"2060-2064","source":"Crossref","is-referenced-by-count":7,"title":["Stability of a pyrimethamine suspension compounded from bulk powder"],"prefix":"10.1093","volume":"74","author":[{"given":"Paul O.","family":"Lewis","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Johnson City Medical Center, Johnson City, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Cluck","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Bill Gatton College of Pharmacy at East Tennessee State University, Johnson City, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica D.","family":"Huffman","sequence":"additional","affiliation":[{"name":"Bill Gatton College of Pharmacy at East Tennessee State University, Johnson City, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda P.","family":"Ogle","sequence":"additional","affiliation":[{"name":"Bill Gatton College of Pharmacy at East Tennessee State University, Johnson City, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy D.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy at East Tennessee State University, Johnson City, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2020071623080465400_b1-0742060","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http:\/\/aidsinfonih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf. (accessed 2016 Feb 16)."},{"key":"2020071623080465400_b2-0742060","doi-asserted-by":"crossref","first-page":"h5114","DOI":"10.1136\/bmj.h5114","article-title":"Drug\u2019s 5000% price rise puts spotlight on soaring US drug costs","volume":"351","author":"McCarthy","year":"2015","journal-title":"BMJ"},{"key":"2020071623080465400_b3-0742060","doi-asserted-by":"crossref","first-page":"ofv177","DOI":"10.1093\/ofid\/ofv177","article-title":"Get rich quick with old generic drugs! The pyrimethamine pricing scandal","volume":"2","author":"Gallant","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2020071623080465400_b4-0742060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archderm.1991.01680040122017","article-title":"Cutaneous drug reactions in human immunodeficiency virus infection","volume":"127","author":"Coopman","year":"1991","journal-title":"Arch Dermatol"},{"key":"2020071623080465400_b5-0742060","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/AAC.42.6.1346","article-title":"Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS","volume":"42","author":"Torre","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623080465400_b6-0742060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4269\/ajtmh.2009.80.583","article-title":"Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994\u20132006","volume":"80","author":"Beraud","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020071623080465400_b7-0742060","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/339551","article-title":"Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237\/ANRS 039 Study","volume":"34","author":"Chirgwin","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020071623080465400_b8-0742060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0140-6736(92)92172-C","article-title":"Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS","volume":"340","author":"Kovacs","year":"1992","journal-title":"Lancet"},{"key":"2020071623080465400_b9-0742060","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/clinids\/24.3.422","article-title":"Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS","volume":"24","author":"Torres","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2020071623080465400_b10-0742060","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/ajhp\/54.23.2714","article-title":"Stability of pyrimethamine in a liquid dosage formulation stored for three months","volume":"54","author":"Nahata","year":"1997","journal-title":"Am J Health-Syst Pharm"},{"key":"2020071623080465400_b11-0742060","volume-title":"37th rev., and The national formulary, 32nd ed. General chapter 1225","author":"The United States pharmacopeia","year":"2014"},{"key":"2020071623080465400_b12-0742060","first-page":"127","volume-title":"Introduction to pharmaceutical chemical analysis","author":"Hansen","year":"2012","edition":"1st"},{"key":"2020071623080465400_b13-0742060","first-page":"1025","volume-title":"Remington: the science and practice of pharmacy","author":"O\u2019Donnell","year":"2006","edition":"21st"},{"key":"2020071623080465400_b14-0742060","volume-title":"37th rev., and The national formulary, 32nd ed. General notices and requirements: applying to standards, tests, assays, and other specifications of the United States Pharmacopeia","author":"The United States pharmacopeia","year":"2014"},{"key":"2020071623080465400_b15-0742060","volume-title":"Daraprim (pyrimethamine) prescribing information","year":"2015"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/24\/2060\/28450317\/ajhp2060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/24\/2060\/28450317\/ajhp2060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T11:51:34Z","timestamp":1594986694000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/24\/2060\/5102710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":15,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,12,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160551","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,15]]},"published":{"date-parts":[[2017,12,15]]}}}